It is estimated about 10-15% of people on HAART for more than two years will develop visceral fat accumulation in the abdomen. In a disappointing finding from the REAL study done by investigators at London’s Chelsea and Westminster Hospital, presented at IAS 2008, little difference was shown in visceral fat levels, over 24 months, from those who shifted to atazanavir/ritonavir versus those remaining on their existing boosted protease inhibitor (70% were on Kaletra). Patients who switched to Atazanavir did have a significant reduction in lipid levels, however.
Presenting the study Dr Graeme Moyle said, “Beyond diet and exercise we’re left with very little to treat visceral fat – it remains a very important clinical challenge.”
www.aidsmap.com
This article was first published in September 2008.
While the content of this article was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.
More stories from this issue.
This article contains medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.
The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.
Posted online: 24 September 2008.
Last updated: 24 September 2008.
More stories about: